About Us

At Viela, we are working to redefine the treatment of autoimmune disease by focusing on pathways shared across various diseases. We believe this approach–which targets the underlying molecular pathogenesis of a disease–may enable us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple diseases with each product candidate. Our unique understanding of autoimmune diseases and their relationship to biological pathways, has enabled us to develop a pipeline of potential first-and best-in-class therapies for various indications, and most recently, secure our first U.S. FDA product approval in neuromyelitis optica spectrum disorder.

Learn More